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The tumor endothelium plays a complex role in cancer
development. Aberrant blood vessels provide structural
support for the tumor, a barrier to immune infiltration,
and also serve as a source of pro-tumorigenic signals. In
accordance with their atypical function, surface protein
expression on tumor vascular cells is distinct. This pro-
vides a unique opportunity for adoptive cell therapy.
Prostate-specific membrane antigen (PSMA) is highly
expressed in the vasculature of a variety of solid tumors,
making it an attractive therapeutic target. We therefore
designed a series of chimeric antigen receptors (CAR)
against PSMA, utilizing an scFv derived from the anti-
PSMA antibody, J591. The scFv was linked to each of
five intracellular signaling domains: Z, 28Z, BBZ, or
28BBZ. In vitro, we found that all CAR bearing T cells
performed equally well against endothelial targets.
However, increased induction of the anti-apoptotic pro-
tein Bcl-xL in T cells bearing the 28BBZ signaling
domain led us to select the 28BBZ CAR for further study
(herein known as P28BBZ). IFNg ELISA and Cr51 release
assays confirmed the functionality of the P28BBZ CAR in
vitro. To assess the ability of the P28BBZ T cells to
recognize PSMA-positive vessels, human endothelial cells
were seeded to a Matrigel basement membrane and
allowed to form microvessels before co-culture with the
CAR bearing T cells. Time-lapse microscopy revealed
that the P28BBZ T cells preferentially homed to PSMA-
positive vessels, destroying them within 24 hours of co-
culture. In vivo, P28BBZ T cells were able to specifically
and durably eliminate PSMA-positive hemangiomas.
PSMA negative hemagiomas, which were injected on the
opposite flank of the same mice, were unaffected by the
injection of the P28BBZ T cells. To further mimic the
tumor microenvironment, mice were injected on each
flank with ID8 ovarian cancer cells mixed with endothe-
lial cells engineered to express a luciferase reporter, or a
luciferase reporter with human PSMA. The PSMA posi-
tive vessels were specifically eliminated upon administra-
tion of the P28BBZ T cells, and a corresponding decrease
in tumor volume was observed. Taken together, these
data demonstrate that T cells harboring the P28BBZ
CAR can specifically eliminate PSMA positive endothelial
targets, and that elimination of these cells impairs tumor
outgrowth.
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